REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Solumiks Herbaceuticals Limited (India)

Main Activities: Miscellaneous Financial Investment Activities
Full name: Solumiks Herbaceuticals Limited Profile Updated: March 06, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2025 Available in: English Download a sample report

solumiks herbaceuticals limited operates in the healthcare sector, specializing in Ayurvedic medications. Its product offerings include Vimliv Fortified Tablets & Syrup, Myostaal, Pyroflex, Nirocil, Ashotone, and Arshkeyt. Solumiks primarily targets the domestic market in India, with operations in Nepal and Sri Lanka, and plans to enter additional Southeast Asian markets.

Legal Address
135 Nanubhai Desai Road
Mumbai; Maharashtra; Postal Code: 400004

Contact Details: Purchase the Solumiks Herbaceuticals Limited report to view the information.

Website: http://www.solumiks.com

Basic Information
Total Employees:
Purchase the Solumiks Herbaceuticals Limited report to view the information.
Registered Capital:
Purchase the Solumiks Herbaceuticals Limited report to view the information.
Financial Auditors:
Purchase the Solumiks Herbaceuticals Limited report to view the information.
Incorporation Date:
October 28, 1994
Key Executives
Purchase this report to view the information.
Promoter Director
Purchase this report to view the information.
Independent Director
Purchase this report to view the information.
Professional Director
Ownership Details
Purchase this report to view the information.
99.99%
Company Performance
Financial values in the chart are available after Solumiks Herbaceuticals Limited report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency INR. Absolute financial data is included in the purchased report.
Net sales revenue
2.07%▲
Total operating revenue
1.75%▲
Operating Profit/Loss (EBIT)
-52.24%▼
EBITDA
-52.17%▼
Net Profit/Loss for the Period
-54.02%▼
Total Assets
5.12%▲
Total Equity
4.69%▲
Operating Profit Margin (ROS)
-7.88%▼
Net Profit Margin
-6.28%▼
Return on Equity (ROE)
-5.72%▼
Quick Ratio
-4.92%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo